Efgartigimod non-responders after the first treatment cycle in generalized myasthenia gravis: a retrospective analysis of predictive factors
Comorbidities including thymoma, other tumors, thyroid disease, and additional autoimmune disorders may predict reduced response to efgartigimod in gMG patients. Systematic evaluation of these factors could help optimize treatment selection.
Authors
- Jing Guo (ORCID: https://orcid.org/0009-0006-6133-3839)
- Jingru Ren (ORCID: https://orcid.org/0000-0002-9186-6621)
- Zhi‐Gang Niu (ORCID: https://orcid.org/0000-0003-4842-1464)
- Haiqiang Jin
- Feng Gao (ORCID: https://orcid.org/0000-0002-7539-6455)
- Nan Zhang (ORCID: https://orcid.org/0000-0002-8309-4262)
- Qing Li (ORCID: https://orcid.org/0000-0003-3087-4692)
- Yiming Zheng (ORCID: https://orcid.org/0000-0002-7947-2769)
- Jianchun Wang (ORCID: https://orcid.org/0009-0006-4972-9339)
- Hong-Jun Hao (ORCID: https://orcid.org/0000-0001-6434-9090)
Institutions
- Peking University (CN)
- Peking University First Hospital (CN)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2025-11-06
- DOI
- https://doi.org/10.3389/fneur.2025.1715486
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China